{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:08:03Z","timestamp":1790741283411,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["PR\u2010PRU\u20101217\u201020401"],"award-info":[{"award-number":["PR\u2010PRU\u20101217\u201020401"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Economics"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Previous studies have estimated that patients served by health systems accrue 59\u201098% of the value generated by new pharmaceuticals. This has led to questions about whether sufficient returns accrue to manufacturers to incentivize socially optimal levels of R&amp;D. These studies have not, however, fully reflected the health opportunity costs imposed by payments for branded pharmaceuticals. We present a framework for estimating how the value generated by new branded pharmaceuticals is shared. We quantify value in net health effects and account for benefits and health opportunity costs in the patent period and post\u2010patent period when generic\/biosimilar products become available. We apply the framework to 12 National Institute for Health and Care Excellence appraisals and show that realized net health effects range from losses of 160%, to gains of 94%, of the potential net health benefits available. In many cases, even in the long run, the benefits of new medicines are not sufficient to offset the opportunity costs of payments to manufacturers, and approval is expected to reduce population health. This cannot be dynamically efficient as it incentivizes future innovation at prices which will also reduce population health. Further work should consider how to reflect these findings in reimbursement policies.<\/jats:p>","DOI":"10.1002\/hec.4393","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:12:10Z","timestamp":1627949530000},"page":"2649-2666","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems"],"prefix":"10.1002","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-9415","authenticated-orcid":false,"given":"Beth","family":"Woods","sequence":"first","affiliation":[{"name":"Centre for Health Economics University of York  York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e","family":"Fox","sequence":"additional","affiliation":[{"name":"Centre for Health Economics University of York  York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sculpher","sequence":"additional","affiliation":[{"name":"Centre for Health Economics University of York  York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2002-4694","authenticated-orcid":false,"given":"Karl","family":"Claxton","sequence":"additional","affiliation":[{"name":"Centre for Health Economics University of York  York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-013-0484-1"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta19140"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta16460"},{"key":"e_1_2_12_5_1","volume-title":"Study on the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards in Europe","author":"Copenhagen Economics","year":"2018"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3086"},{"key":"e_1_2_12_7_1","volume-title":"Accelerated access collaborative for health technologies. IA No: 13003","author":"Department of Health","year":"2017"},{"key":"e_1_2_12_8_1","volume-title":"Drugs and pharmaceutical electronic market information tool (eMIT) national database","author":"Department of Health and Social Care","year":"2017"},{"key":"e_1_2_12_9_1","volume-title":"NICE's technology appraisal and highly specialised technology work programmes\u2014Charging and Appeals Panels","author":"Department of Health and Social Care","year":"2018"},{"key":"e_1_2_12_10_1","volume-title":"2018 Statutory scheme \u2013 branded medicines pricing","author":"Department of Health and Social Care","year":"2018"},{"key":"e_1_2_12_11_1","volume-title":"2014 Pharmaceutical Price Regulation Scheme (PPRS) and The Branded Health Service Medicines (Costs) Regulations 2018. Aggregate net sales and payment information 27 February 2019","author":"Department of Health & Social Care","year":"2019"},{"key":"e_1_2_12_12_1","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond M. F.","year":"2015"},{"key":"e_1_2_12_13_1","volume-title":"Pharmaceutical sector inquiry final report","author":"European Commission","year":"2009"},{"key":"e_1_2_12_14_1","volume-title":"Measurement of medicines expenditure in the context of the 2014\u201018 PPRS","author":"Ferraro J.","year":"2018"},{"key":"e_1_2_12_15_1","volume-title":"US$54 billion worth of biosimilar patents expiring before 2020","author":"GaBI Online","year":"2011"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.08.014"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.825"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2008.05.010"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198\u2010011\u20100315\u20101"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.04.1926"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.006"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v4.30754"},{"key":"e_1_2_12_23_1","volume-title":"Infliximab for the treatment of adults with psoriasis","author":"National Institute for Health and Care Excellence","year":"2008"},{"key":"e_1_2_12_24_1","volume-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"e_1_2_12_25_1","volume-title":"Infliximab and adalimumab for the treatment of Crohn's disease","author":"National Institute for Health and Care Excellence","year":"2010"},{"key":"e_1_2_12_26_1","volume-title":"Guide to the methods of technology appraisal 2013: Process and methods","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"e_1_2_12_27_1","volume-title":"Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"e_1_2_12_28_1","volume-title":"TNF\u2010alpha inhibitors for ankylosing spondylitis and non\u2010radiographic axial spondyloarthritis","author":"National Institute for Health and Care Excellence","year":"2016"},{"key":"e_1_2_12_29_1","volume-title":"Tisagenlecleucel\u2010T for treating relapsed or refractory diffuse large B\u2010cell lymphoma","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"e_1_2_12_30_1","volume-title":"Commissioning framework for biological medicines (including biosimilar medicines)","author":"NHS","year":"2017"},{"key":"e_1_2_12_31_1","volume-title":"NHS England strikes world leading deal to help eliminate hepatitis C","author":"NHS","year":"2019"},{"key":"e_1_2_12_32_1","volume-title":"Reference prices for adalimumab","author":"NHS","year":"2019"},{"key":"e_1_2_12_33_1","volume-title":"National cancer drugs fund list","author":"NHS","year":"2020"},{"key":"e_1_2_12_34_1","volume-title":"Medicines optimisation dashboard","author":"NHS Business Services Authority","year":"2019"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh\u20102018\u2010000964"},{"key":"e_1_2_12_36_1","volume-title":"How is evidence of health opportunity cost used: Key challenges","author":"Palnoch D.","year":"2019"},{"key":"e_1_2_12_37_1","volume-title":"Theoretical models of the cost\u2010effectiveness threshold, value assessment, and health care system sustainability","author":"Pandey H.","year":"2018"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00988-2"},{"key":"e_1_2_12_39_1","volume-title":"Comparing the EQ\u20105D\u20103L and 5L versions. What are the implications for model\u2010based cost effectiveness estimates","author":"Pennington B.","year":"2018"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273\u2010018\u20100701\u2010y"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.11.021"},{"key":"e_1_2_12_42_1","volume-title":"Prescribing outlook new medicines\u2014September 2012","author":"UK Medicines Information","year":"2012"},{"key":"e_1_2_12_43_1","volume-title":"Prescribing outlook new medicines\u2014September 2013","author":"UK Medicines Information","year":"2013"},{"key":"e_1_2_12_44_1","volume-title":"Prescribing outlook new medicines\u2014September 2014","author":"UK Medicines Information","year":"2014"},{"key":"e_1_2_12_45_1","volume-title":"Prescribing outlook new medicines\u2014September 2015","author":"UK Medicines Information","year":"2015"},{"key":"e_1_2_12_46_1","volume-title":"Prescribing outlook new medicines\u2014September 2016","author":"UK Medicines Information","year":"2016"}],"container-title":["Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hec.4393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hec.4393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hec.4393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T06:34:31Z","timestamp":1692426871000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hec.4393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/hec.4393"],"URL":"https:\/\/doi.org\/10.1002\/hec.4393","archive":["Portico"],"relation":{},"ISSN":["1057-9230","1099-1050"],"issn-type":[{"value":"1057-9230","type":"print"},{"value":"1099-1050","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"2020-10-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}